ResMed (NYSE:RMD) Price Target Lowered to $225.00 at Wells Fargo & Company

ResMed (NYSE:RMD) had its price target decreased by analysts at Wells Fargo & Company from $227.00 to $225.00 in a report issued on Wednesday,Benzinga reports. The firm presently has an “equal weight” rating on the medical equipment provider’s stock. Wells Fargo & Company‘s target price would suggest a potential upside of 2.45% from the stock’s previous close.

A number of other equities research analysts have also issued reports on RMD. Weiss Ratings lowered shares of ResMed from a “hold (c+)” rating to a “hold (c)” rating in a research note on Friday, May 22nd. Citigroup lowered their price objective on ResMed from $340.00 to $270.00 and set a “buy” rating for the company in a report on Monday, June 15th. Morgan Stanley restated an “equal weight” rating and set a $230.00 price objective (down from $286.00) on shares of ResMed in a research note on Wednesday, June 17th. JPMorgan Chase & Co. assumed coverage on ResMed in a research report on Wednesday, April 15th. They issued an “overweight” rating for the company. Finally, Royal Bank Of Canada boosted their price target on ResMed from $314.00 to $321.00 and gave the company an “outperform” rating in a report on Friday, May 1st. One equities research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and six have given a Hold rating to the company’s stock. Based on data from MarketBeat, ResMed currently has a consensus rating of “Moderate Buy” and an average target price of $270.64.

ResMed Trading Up 0.6%

NYSE:RMD opened at $219.62 on Wednesday. The stock has a market cap of $31.86 billion, a price-to-earnings ratio of 21.18, a price-to-earnings-growth ratio of 1.28 and a beta of 0.78. ResMed has a one year low of $180.26 and a one year high of $293.81. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.33 and a current ratio of 3.01. The business’s 50-day simple moving average is $201.12 and its 200 day simple moving average is $228.95.

ResMed (NYSE:RMD) last announced its earnings results on Thursday, April 30th. The medical equipment provider reported $2.86 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.79 by $0.07. The company had revenue of $1.43 billion for the quarter, compared to analyst estimates of $1.42 billion. ResMed had a return on equity of 25.35% and a net margin of 27.44%.ResMed’s quarterly revenue was up 10.8% on a year-over-year basis. During the same period in the prior year, the company posted $2.37 EPS. As a group, sell-side analysts predict that ResMed will post 11.13 earnings per share for the current fiscal year.

Insider Buying and Selling at ResMed

In other ResMed news, CEO Michael J. Farrell sold 4,991 shares of the stock in a transaction on Monday, June 8th. The stock was sold at an average price of $193.96, for a total value of $968,054.36. Following the sale, the chief executive officer directly owned 466,256 shares of the company’s stock, valued at $90,435,013.76. This trade represents a 1.06% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 0.65% of the company’s stock.

Institutional Trading of ResMed

Institutional investors have recently made changes to their positions in the stock. International Assets Investment Management LLC bought a new position in shares of ResMed during the 4th quarter valued at about $25,000. ORG Partners LLC lifted its stake in ResMed by 181.6% during the fourth quarter. ORG Partners LLC now owns 107 shares of the medical equipment provider’s stock valued at $26,000 after purchasing an additional 69 shares during the last quarter. Imprint Wealth LLC acquired a new stake in ResMed during the third quarter valued at approximately $26,000. WFA of San Diego LLC bought a new stake in ResMed during the second quarter worth approximately $26,000. Finally, Sunbelt Securities Inc. acquired a new position in ResMed in the third quarter worth approximately $31,000. 54.98% of the stock is owned by institutional investors and hedge funds.

Key Stories Impacting ResMed

Here are the key news stories impacting ResMed this week:

• Positive Sentiment: ResMed is divesting MatrixCare to concentrate on higher-growth sleep and home-based care opportunities, which could improve long-term growth and capital efficiency. ResMed to sell software business MatrixCare for $490 million
• Positive Sentiment: The $490 million cash proceeds may give ResMed more flexibility to reinvest in product innovation, margin expansion, or other strategic initiatives. Resmed Announces Agreement to Sell MatrixCare Business
• Neutral Sentiment: The sale is expected to close in ResMed’s first fiscal quarter of 2027, so the financial impact will not be immediate and still depends on regulatory approvals. Resmed Divests MatrixCare to Refocus on Core Sleep Care
• Neutral Sentiment: Recent commentary also points to continued analyst optimism and growth expectations, which may be reinforcing the stock’s strength around the news. Will ResMed (RMD) Beat Estimates Again in Its Next Earnings Report?
• Negative Sentiment: Selling MatrixCare also means ResMed is exiting a software line that served more than 15,000 providers, which could be seen as narrowing diversification. ResMed’s $490m MatrixCare sale: What it means

ResMed Company Profile

ResMed (NYSE: RMD) is a global medical device and cloud-connectivity company focused on improving outcomes for people with sleep-disordered breathing and chronic respiratory conditions. Founded in 1989, the company is headquartered in San Diego, California, and develops, manufactures and distributes a range of devices and software used by patients, clinicians and providers worldwide.

ResMed’s product portfolio centers on noninvasive ventilation and sleep therapy equipment, including continuous positive airway pressure (CPAP) and bilevel devices, masks and related accessories for the treatment of obstructive sleep apnea and other respiratory disorders.